In practice, this means that when medicinal chemists discover
a promising kinase inhibitor that exists as two interchanging arrangements, they actually have two different inhibitors.
Not exact matches
These results not only show
promise on a new targeted therapy to treat this malignancy, as PI3K
inhibitors are already used in the clinical practice, but also unravel a new function of the PI3K
kinase in cancer biology through its role in promoting metastasis.
The first trial to take place as a result of the CDP initiative is a Phase I clinical trial of GlaxoSmithKline's aurora
kinase inhibitor GSK - 1070916A - a
promising new drug to treat solid tumours.